CCM
IDYA icon

CAAS Capital Management’s IDEAYA Biosciences IDYA Stock Holding History

CAAS Capital Management’s Portfolio IDYA Stock Details IDYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-169,080
Closed -$2.52M – 864
2022
Q3 		$2.52M Buy
+169,080
New +$2.2M 0.12% 241
2020
Q3 		– Sell
-25,346
Closed -$360K – 540
2020
Q2 		$360K Buy
+25,346
New +$200K 0.01% 337

Other funds holding IDYA

LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CAAS Capital Management's IDYA Position: Q4 2022 in Review

CAAS Capital Management sold out of IDEAYA Biosciences (IDYA) in Q4 2022, closing a stake of 169,080 shares — an estimated $2.52M sold.

CAAS Capital Management first reported a position in IDYA in Q2 2020 and held it in 2 quarters. The position peaked at $2.52M in Q3 2022. 117 funds tracked by Wall St. Rank hold IDYA as of Q4 2022.

  • CAAS Capital Management reported no remaining IDEAYA Biosciences position as of Q4 2022 after selling out during the quarter.
  • CAAS Capital Management sold 169,080 IDEAYA Biosciences shares in Q4 2022, an estimated $2.52M.
  • CAAS Capital Management first reported a position in IDEAYA Biosciences in Q2 2020 and held it in 2 quarters.
  • CAAS Capital Management's IDEAYA Biosciences position peaked at $2.52M in Q3 2022.
  • 117 funds tracked by Wall St. Rank held IDEAYA Biosciences as of Q4 2022.

Based on CAAS Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.